The value of piperacillin sodium and tazobactam sodium in the treatment of respiratory tract infections in the elderly
Objective To explore the clinical effect of piperacillin sodium and tazobactam sodium in the treatment of respiratory tract infections in the elderly.Methods A total of 68 elderly patients with respiratory tract infection were randomly divided into a control group and an observation group,each with 34 cases.The control group was treated with mezlocillin sodium and sulbactam sodium,and the observation group was treated with piperacillin sodium and tazobactam sodium.Both groups were compared in terms of clinical efficacy,clinical symptom improvement(time for fever relief,cough relief,pharyngeal pain relief,and pharyngeal congestion disappearance),adverse reactions(muscle spasms,rash,diarrhea,fever),plasma leukocyte count,inflammatory factors[C-reactive protein(CRP)and procalcitonin(PCT)],cellular immune function[CD3+,CD4+,CD8+,CD4+/CD8+and natural killer(NK)cell]before and after treatment.Results The total effective rate of the observation group was 94.12%,which was higher than 76.47%of the control group,and the difference was statistically significant(χ2=4.221,P<0.05).In observation group,the time for fever relief,cough relief,pharyngeal pain relief,and pharyngeal congestion disappearance were(2.38±0.36),(3.51±0.47),(3.89±0.67),and(3.86±0.60)d,which were shorter than(3.19±0.46),(5.11±0.59),(5.69±0.73),and(5.72±0.67)d in the control group,and the difference was statistically significant(t=8.086,12.368,10.593,12.059;P<0.05).After treatment,the observation group had white blood cell count of(6.06±0.80)×109/L,CRP of(6.51±1.28)mg/L and PCT of(0.34±0.04)ng/ml,which were lower than(8.70±1.12)×109/L,(8.59±2.07)mg/L and(0.59±0.10)ng/ml in the control group;the observation group had CD4+of(42.12±2.62)%and CD4+/CD8+of(1.28±0.29),which were higher than(36.80±2.94)%and(1.13±0.26)in the control group;the difference was statistically significant(P<0.05).There was no significant difference in CD3+,CD8+and NK cell between the two groups(P>0.05).The incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(χ2=3.981,P<0.05).Conclusion Using piperacillin sodium and tazobactam sodium in the treatment of elderly respiratory tract infections can promote the recovery of the disease,and is conducive to the recovery of white blood cell count,reduce inflammatory response,promote the improvement of cellular immune function,and accelerate the relief of clinical symptoms.The clinical effect is obvious,and the safety is high,so it is worthy of clinical promotion.
万方数据
维普
